Draconis Pharma was founded in October 2011 after the acquisition of the Drug Discovery unit from the biopharmaceutical company Palau Pharma S.A. This operation allowed Draconis Pharma to take on a team of experienced scientific staff and to acquire cutting-edge technology in the area of drug discovery.
Draconis Pharma has collaborated with the technological center LEITAT, a member of TECNIO, recognized by certification created by the Government of Catalonia, through ACCIÓ, which aims to collaborate with companies and institutions by adding technological value to both products and processes, and focuses its activity on research, development and industrial innovation (R+D+2i). The Draconis Pharma business model aims to become an innovative leader in the European pharmaceutical and biotechnology industry.
Draconis Pharma S.L. is focused on providing scientific and technological services to pharmaceutical and biotechnology companies, aimed at supporting drug discovery at different stages of research, such as target validation, hit-finding, hit-to-lead and lead optimization towards the release of a robust and well-characterized preclinical candidate. Our scientific team comes entirely from the pharmaceutical R&D industry. They offer Draconis Pharma wide and proven experience in the different areas within drug discovery such as medicinal chemistry, analytical profiling, cell-based assays, in-vivo efficacy, ADME & PK and preliminary studies to determine toxicity and safety profiles.
Besides the service business, Draconis Pharma also participates in consortium and projects for the discovery and development of innovative technology or novel therapies for the treatment of inflammatory diseases and related disorders, such as Cancer.